Biotech Values

[biomaven0]

I guess we might have to wait and see what the narrowed claims look like.

Here is the main claim as it presently stands:

A compound that inhibits hypoxia inducible factor (HIF) hydroxylase activity for use in treating or preventing iron deficiency in a subject, wherein the compound is a structural mimetic of 2-oxoglutarate.

also:

The compound of claim 1 for the use of that claim, wherein the iron deficiency is associated with a disorder selected from the group consisting of anemia, iron deficiency anemia, microcytic anemia, inflammation, infection, immunodeficiency disorder and neoplastic disorder.
The compound of claim 1 for the use of that claim, wherein the compound is for use in increasing iron absorption.


Akebia might argue that treating anemia without IV iron using their drug is not covered by those claims - I would beg to differ (as those claims presently stand).